{"id":2755,"date":"2026-08-28T12:00:00","date_gmt":"2026-08-28T16:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2755"},"modified":"2026-08-28T16:38:12","modified_gmt":"2026-08-28T20:38:12","slug":"vivace-formalizes-leadership-ahead-of-phase-iii","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2755","title":{"rendered":"Vivace Formalizes Leadership Ahead of Phase III"},"content":{"rendered":"

Company:<\/strong> Vivace Therapeutics · Event Type:<\/strong> Leadership Transition · New CEO:<\/strong> Craig Gibbs · Lead Program:<\/strong> VT3989 (Mesothelioma) · Date:<\/strong> August 26, 2026<\/p>\n

\"20260828_Vivace_Therapeutics_Leadership_Tracker\"<\/p>\n

Summary<\/h4>\n

Vivace Therapeutics named Craig Gibbs as chief executive officer and appointed Ellen Lubman as chief business and strategy officer, formalizing a leadership transition from founder Sofie Qiao as the company advances VT3989 toward a pivotal Phase III trial in mesothelioma with FDA “safe to proceed” clearance.<\/p>\n

What Happened<\/h4>\n

Craig Gibbs has served as CEO and board member since May 2026, with the appointment publicly announced August 26. Founder Sofie Qiao moves to an advisor role and remains CEO of a separate company, Virtuoso Therapeutics. Ellen Lubman joins as chief business and strategy officer, and Tim Clackson joins the board as an independent director. The announcement coincides with FDA “safe to proceed” clearance for the pivotal sTEADfast Phase III trial of VT3989, a TEAD inhibitor, in mesothelioma.<\/p>\n

Deep Analysis<\/h4>\n

Leadership formalization timed to coincide with a pivotal trial clearance is a common pattern signaling that a company is professionalizing its executive team ahead of a capital-intensive, high-visibility late-stage trial. The founder’s transition to an advisory role while retaining CEO duties at a separate company suggests a planned, non-adversarial succession rather than a forced departure. Tim Clackson’s addition as an independent board director may bring late-stage biotech governance experience relevant to Phase III execution and eventual commercialization planning. TEAD inhibitors, which target the Hippo signaling pathway, are a competitive emerging mechanism in mesothelioma, a disease with very limited treatment options.<\/p>\n

Company and Product Background<\/h4>\n

Vivace Therapeutics is a clinical-stage biotechnology company developing VT3989, an oral TEAD auto-palmitoylation inhibitor targeting the Hippo signaling pathway, with mesothelioma as its lead indication given the pathway’s known role in NF2-mutant and other Hippo-dysregulated tumors.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Leadership Change<\/td>\nCraig Gibbs formalized as CEO (in role since May 2026); Ellen Lubman joins as Chief Business and Strategy Officer<\/td>\n<\/tr>\n
Board Addition<\/td>\nTim Clackson joins as independent director<\/td>\n<\/tr>\n
Founder Transition<\/td>\nSofie Qiao moves to advisor, remains CEO of Virtuoso Therapeutics<\/td>\n<\/tr>\n
Regulatory Milestone<\/td>\nFDA “safe to proceed” clearance for pivotal sTEADfast Phase III trial<\/td>\n<\/tr>\n
Signal Type<\/td>\nLeadership\/governance signal coinciding with clinical milestone<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A planned, non-adversarial leadership transition combined with an experienced board addition and FDA clearance to proceed into a pivotal Phase III trial suggests Vivace is building the organizational infrastructure needed to execute a late-stage program in a disease with substantial unmet need.<\/p>\n

Bear case:<\/strong> Leadership transitions immediately preceding capital-intensive pivotal trials can also reflect a company preparing for a challenging fundraising environment or bringing in commercially oriented leadership because the founding team lacked late-stage execution experience.<\/p>\n

InSilens Take<\/h4>\n

The governance changes read as constructive preparation rather than distress signals, but the substantive news is the FDA clearance to proceed into pivotal Phase III testing for VT3989, the leadership formalization is best read as supporting infrastructure for that trial, not news in its own right.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Neutral · Confidence:<\/strong> High on facts, Low on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

Vivace Therapeutics named Craig Gibbs as chief executive officer and appointed Ellen Lubman as chief business and strategy officer, formalizing a leadership transition from founder Sofie Qiao as the company advances VT3989 toward a…<\/p>\n","protected":false},"author":1,"featured_media":2756,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[196],"tags":[464,465,463],"class_list":["post-2755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-leadership-tracker","tag-mesothelioma","tag-tead-inhibitor","tag-vivace-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2755"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2755\/revisions"}],"predecessor-version":[{"id":2775,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2755\/revisions\/2775"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2756"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}